This study is enrolling by invitation. It focuses on depression and currently lists participation information in the United States.
This study is testing Azetukalner, an experimental Kv7 potassium-channel opener, for people with depression. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to Azetukalner, but direct benefit is not guaranteed.
The official record suggests in-person participation through a lab, with sites including Ima Clinical Research - Phoenix, Sanro Clinical Research Group, Llc in Bryant, and Woodland International Research Group in Little Rock. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and having a stable enough treatment background for the study, while common reasons not to take part include active substance or alcohol problems that could affect the results and pregnancy or breastfeeding. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring observational follow-up for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Xenon Pharmaceuticals Inc.. Based on the sponsor name or official registry information, it appears to be another type of organization. You should verify the details in the official registry record.
This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.